Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
Moodys
UBS
McKinsey
Dow
Fish and Richardson
Cerilliant
Chubb

Generated: January 24, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLANZAPINE

« Back to Dashboard

Clinical Trials for Olanzapine

Trial ID Title Status Sponsor Phase Summary
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000374 Treatment for First-Episode Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Olanzapine

Condition Name

Condition Name for Olanzapine
Intervention Trials
Schizophrenia 204
Bipolar Disorder 53
Schizoaffective Disorder 52
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olanzapine
Intervention Trials
Schizophrenia 216
Psychotic Disorders 82
Disease 74
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olanzapine

Trials by Country

Trials by Country for Olanzapine
Location Trials
United States 878
Canada 63
Spain 36
Germany 33
China 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olanzapine
Location Trials
New York 72
California 62
Texas 48
Ohio 47
Florida 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olanzapine

Clinical Trial Phase

Clinical Trial Phase for Olanzapine
Clinical Trial Phase Trials
Phase 4 147
Phase 3 102
Phase 2/Phase 3 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olanzapine
Clinical Trial Phase Trials
Completed 283
Recruiting 40
Terminated 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olanzapine

Sponsor Name

Sponsor Name for Olanzapine
Sponsor Trials
Eli Lilly and Company 82
National Institute of Mental Health (NIMH) 30
Pfizer 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olanzapine
Sponsor Trials
Other 363
Industry 236
NIH 45
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
McKinsey
Harvard Business School
Chinese Patent Office
Colorcon
Accenture
McKesson
Federal Trade Commission
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.